Metabolic modulation during intestinal fibrosis

Area of Science:

• Gastroenterology
• Cellular and Molecular Medicine
• Fibrosis Research

Background:

• Intestinal fibrosis is a major challenge in managing inflammatory bowel diseases (IBD), particularly Crohn's disease, leading to bowel stenosis.
• Current IBD therapies do not effectively prevent fibrotic complications, indicating the involvement of inflammation-independent mechanisms in intestinal fibrogenesis.
• The significant patient burden and lack of anti-fibrotic treatments necessitate exploring novel therapeutic avenues.

Purpose of the Study:

• To review metabolic alterations associated with fibrotic diseases.
• To summarize the evidence for metabolic shifts in intestinal fibrosis.
• To highlight potential therapeutic opportunities arising from understanding fibroblast metabolic reprogramming.

Main Methods:

• Literature review of metabolic changes in fibrotic diseases.
• Analysis of existing data on cellular metabolism in intestinal fibrosis.
• Synthesis of evidence linking fibroblast metabolic reprogramming to fibrogenesis.

Main Results:

• Metabolic modifications are increasingly recognized as pathogenic drivers in fibroproliferative diseases.
• Activated fibroblasts, key mediators of fibrosis, undergo a switch in cellular metabolism.
• Evidence suggests a distinct metabolic shift occurs during the development of intestinal fibrosis.

Conclusions:

• Targeting metabolic pathways in activated fibroblasts presents a promising strategy for developing novel anti-fibrotic therapies for IBD.
• Understanding the specific metabolic reprogramming in intestinal fibrosis is crucial for therapeutic innovation.
• Redirecting research towards inflammation-independent fibrotic mechanisms, particularly metabolic alterations, is essential.